Mikael Finder1,2, Geraldine B Boylan3,4, Deirdre Twomey3,4, Caroline Ahearne3,4, Deirdre M Murray3,4, Boubou Hallberg1,2. 1. Division of Paediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. 2. Neonatal Department, Karolinska University Hospital, Stockholm, Sweden. 3. INFANT Research Centre, Ireland, University College Cork, Cork, Ireland. 4. Department of Paediatrics and Child Health, Cork University Hospital, Cork, Ireland.
Abstract
Importance: Therapeutic hypothermia reduces risk of death and disability in infants with moderate to severe hypoxic ischemic encephalopathy (HIE). Randomized clinical trials of therapeutic hypothermia to date have not included infants with mild HIE because of a perceived good prognosis. Objective: To test the hypothesis that children with mild HIE have worse neurodevelopmental outcomes than their healthy peers. Design, Setting, and Participants: Analysis of pooled data from 4 prospective cohort studies in Cork, Ireland, and Stockholm, Sweden, between January 2007 and August 2015. The dates of data analysis were September 2017 to June 2019. Follow-up was performed at age 18 to 42 months. In this multicenter cohort study, all children were born or treated at the tertiary centers of Cork University Maternity Hospital, Cork, Ireland, or Karolinska University Hospital, Stockholm, Sweden. In all, 690 children were eligible for this study. Exposures: At discharge, all children were categorized into the following 5 groups using a modified Sarnat score: healthy controls, perinatal asphyxia (PA) without HIE, mild HIE, moderate HIE, and severe HIE. Main Outcomes and Measures: Cognitive, language, and motor development were assessed with the Bayley Scales of Infant and Toddler Development, Third Edition (BSITD-III). The BSITD-III scores are standardized to a mean (SD) of 100 (15), with lower scores indicating risk of developmental delay. Results: Of the 690 children eligible for this study, 2-year follow-up data were available in 471 (mean [SD] age at follow-up, 25.6 [5.7] months; 54.8% male), including 152 controls, 185 children with PA without HIE, and 134 children with HIE, of whom 14 had died. Infants with mild HIE (n = 55) had lower cognitive composite scores compared with controls, with a mean (SD) of 97.6 (11.9) vs 103.6 (14.6); the crude mean difference was -6.0 (95% CI, -9.9 to -2.1), and the adjusted mean difference was -5.2 (95% CI, -9.1 to -1.3). There was no significant difference in the mean cognitive composite scores between untreated children (n = 47) with mild HIE and surviving children with moderate HIE (n = 53) treated with therapeutic hypothermia, with a crude mean difference for mild vs moderate of -2.2 (95% CI, -8.1 to 3.7). Conclusions and Relevance: This study's findings suggest that, at age 2 years, the cognitive composite scores of children with a history of mild HIE may be lower than those of a contemporaneous control group and may not be significantly different from those of survivors of moderate HIE treated with therapeutic hypothermia.
Importance: Therapeutic hypothermia reduces risk of death and disability in infants with moderate to severe hypoxic ischemic encephalopathy (HIE). Randomized clinical trials of therapeutic hypothermia to date have not included infants with mild HIE because of a perceived good prognosis. Objective: To test the hypothesis that children with mild HIE have worse neurodevelopmental outcomes than their healthy peers. Design, Setting, and Participants: Analysis of pooled data from 4 prospective cohort studies in Cork, Ireland, and Stockholm, Sweden, between January 2007 and August 2015. The dates of data analysis were September 2017 to June 2019. Follow-up was performed at age 18 to 42 months. In this multicenter cohort study, all children were born or treated at the tertiary centers of Cork University Maternity Hospital, Cork, Ireland, or Karolinska University Hospital, Stockholm, Sweden. In all, 690 children were eligible for this study. Exposures: At discharge, all children were categorized into the following 5 groups using a modified Sarnat score: healthy controls, perinatal asphyxia (PA) without HIE, mild HIE, moderate HIE, and severe HIE. Main Outcomes and Measures: Cognitive, language, and motor development were assessed with the Bayley Scales of Infant and Toddler Development, Third Edition (BSITD-III). The BSITD-III scores are standardized to a mean (SD) of 100 (15), with lower scores indicating risk of developmental delay. Results: Of the 690 children eligible for this study, 2-year follow-up data were available in 471 (mean [SD] age at follow-up, 25.6 [5.7] months; 54.8% male), including 152 controls, 185 children with PA without HIE, and 134 children with HIE, of whom 14 had died. Infants with mild HIE (n = 55) had lower cognitive composite scores compared with controls, with a mean (SD) of 97.6 (11.9) vs 103.6 (14.6); the crude mean difference was -6.0 (95% CI, -9.9 to -2.1), and the adjusted mean difference was -5.2 (95% CI, -9.1 to -1.3). There was no significant difference in the mean cognitive composite scores between untreated children (n = 47) with mild HIE and surviving children with moderate HIE (n = 53) treated with therapeutic hypothermia, with a crude mean difference for mild vs moderate of -2.2 (95% CI, -8.1 to 3.7). Conclusions and Relevance: This study's findings suggest that, at age 2 years, the cognitive composite scores of children with a history of mild HIE may be lower than those of a contemporaneous control group and may not be significantly different from those of survivors of moderate HIE treated with therapeutic hypothermia.
Authors: Jeffrey M Perlman; Jonathan Wyllie; John Kattwinkel; Dianne L Atkins; Leon Chameides; Jay P Goldsmith; Ruth Guinsburg; Mary Fran Hazinski; Colin Morley; Sam Richmond; Wendy M Simon; Nalini Singhal; Edgardo Szyld; Masanori Tamura; Sithembiso Velaphi Journal: Circulation Date: 2010-10-19 Impact factor: 29.690
Authors: Mariëlle van Handel; Leo de Sonneville; Linda S de Vries; Marian J Jongmans; Hanna Swaab Journal: Dev Neuropsychol Date: 2012 Impact factor: 2.253
Authors: Susan E Jacobs; Marie Berg; Rod Hunt; William O Tarnow-Mordi; Terrie E Inder; Peter G Davis Journal: Cochrane Database Syst Rev Date: 2013-01-31
Authors: Janet M Rennie; Linda S de Vries; Mats Blennow; Adrienne Foran; Divyen K Shah; Vicki Livingstone; Alexander C van Huffelen; Sean R Mathieson; Elena Pavlidis; Lauren C Weeke; Mona C Toet; Mikael Finder; Raga Mallika Pinnamaneni; Deirdre M Murray; Anthony C Ryan; William P Marnane; Geraldine B Boylan Journal: Arch Dis Child Fetal Neonatal Ed Date: 2018-11-24 Impact factor: 5.747
Authors: Denis Azzopardi; Brenda Strohm; Neil Marlow; Peter Brocklehurst; Aniko Deierl; Oya Eddama; Julia Goodwin; Henry L Halliday; Edmund Juszczak; Olga Kapellou; Malcolm Levene; Louise Linsell; Omar Omar; Marianne Thoresen; Nora Tusor; Andrew Whitelaw; A David Edwards Journal: N Engl J Med Date: 2014-07-10 Impact factor: 91.245
Authors: Dennis Azzopardi; Peter Brocklehurst; David Edwards; Henry Halliday; Malcolm Levene; Marianne Thoresen; Andrew Whitelaw Journal: BMC Pediatr Date: 2008-04-30 Impact factor: 2.125
Authors: R Scott Watson; Sue R Beers; Lisa A Asaro; Cheryl Burns; Min Jung Koh; Mallory A Perry; Derek C Angus; David Wypij; Martha A Q Curley Journal: JAMA Date: 2022-03-01 Impact factor: 157.335
Authors: Daan R M G Ophelders; Ruth Gussenhoven; Luise Klein; Reint K Jellema; Rob J J Westerlaken; Matthias C Hütten; Jeroen Vermeulen; Guido Wassink; Alistair J Gunn; Tim G A M Wolfs Journal: Cells Date: 2020-08-10 Impact factor: 6.600